Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort.
Sandra Esperanza Díaz-CasasXimena Briceño-MoralesLeidy Juliana Puerto-HortaCarlos Lehmann-MosqueraMartha Cecilia Orozco-OspinoLuis Hernán Guzmán-AbiSaabJavier Ángel-AristizábalMauricio García-MoraCarlos Alfonso Duarte-TorresIván Fernando Mariño-LozanoClara Briceño-MoralesRicardo Sánchez-PedrazaPublished in: The oncologist (2022)
In this cohort, patients with luminal A tumors and those who underwent tumor surgery given that they presented clinical benefit (CB) after initial systemic treatment, had the lowest progression and mortality rates. Overall, OS was inferior to other series due to high tumor burden and difficulties in accessing and continuing oncological treatments.